Lataa...
Anti‐angiogenic effects of novel cyclin‐dependent kinase inhibitors with a pyrazolo[4,3‐d]pyrimidine scaffold
BACKGROUND AND PURPOSE: Cyclin‐dependent kinase 5 (CDK5) has recently emerged as an attractive target in several tumour entities. Inhibition of CDK5 has been shown to have anti‐angiogenic effects in vitro and in vivo. However, potent inhibitors of CDK5, which can be applied in vivo, are still scarce...
Tallennettuna:
| Julkaisussa: | Br J Pharmacol |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4978162/ https://ncbi.nlm.nih.gov/pubmed/27390037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13546 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|